Torrent buys way into controlled substances

Torrent Pharmaceuticals has ventured into the US controlled substances sector by paying an undisclosed fee for local generics and OTC player Bio-Pharm Inc (BPI). “This acquisition is an important step for increasing Torrent’s presence in the US, is consistent with our strategy of dosage-form diversification, and provides us with new capabilities, including manufacturing and research and development presence in the US,” the Indian company commented.

Torrent Pharmaceuticals has ventured into the US controlled substances sector by paying an undisclosed fee for local generics and OTC player Bio-Pharm Inc (BPI). “This acquisition is an important step for increasing Torrent’s presence in the US, is consistent with our strategy of dosage-form diversification, and provides us with new capabilities, including manufacturing and research and development presence in the US,” the Indian company commented.

“Established in 1992,” Torrent explained, “BPI has a proven track record in the research, development and manufacturing of oral solutions,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Sandoz Starts Construction On $440m Slovenian Biosimilars Plant

 
• By 

Sandoz has begun constructing a major biosimilars manufacturing facility in Slovenia that is set to become operational in 2028. A $440m investment in the project adds to local biosimilars initiatives that together total over $1bn, helping Sandoz to move out of the shadow of former parent Novartis.

Torrent Acquires JB Chem In 2025’s Biggest Deal For Indian Pharma

 
• By 

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment.

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

 
• By 

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.